Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163201 | 0.94 | DAGLA (0.46) | CES1DAGLAFAAH | |
| SCHEMBL2162439 | 0.89 | CES1 (0.42) | CES1DAGLAFAAH | |
| SCHEMBL2162388 | 0.86 | CES1 (0.49) | CES1DAGLAFAAH | |
| SCHEMBL2162945 | 0.83 | DAGLA (0.38) | CES1DAGLAFAAH | |
| SCHEMBL2162609 | 0.82 | DAGLA (0.37) | CES1DAGLAFAAH | |
| SCHEMBL2162662 | 0.82 | DAGLA (0.45) | CES1DAGLAFAAH | |
| SCHEMBL2162885 | 0.82 | DAGLA (0.45) | CES1DAGLAFAAH | |
| SCHEMBL2162516 | 0.81 | FAAH (0.38) | CES1DAGLAFAAH | |
| SCHEMBL2163279 | 0.80 | CES1 (0.60) | CES1DAGLAGSK3BFAAH | |
| SCHEMBL2162537 | 0.80 | DAGLA (0.48) | CES1DAGLAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2009154785-A2 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302607-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | ACACA, AKR1C4, HSD17B12 | CES1 7/4885DAGLA 921/4885GSK3B 1742/4885 |
| US-20110184026-A1 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | ACACA, AKR1C4, HSD17B12 | CES1 7/4885DAGLA 853/4885GSK3B 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.